Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Follow-On" Biologics Framework Development Will Become More Public Process, FDA's Kweder Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency is still struggling with scientific issues, the Office of New Drugs deputy director says. A delay in the public comment process should not be perceived as FDA "just being secretive."
Advertisement

Related Content

Follow-On Biologics Guidance Delayed, Agency Tells BIO
Follow-On Biologics Guidance Delayed, Agency Tells BIO
FDA Follow-On Biologics Guidance Will Have Broad Scope, But Not "Break New Ground"
FDA Follow-On Biologics Guidance Will Have Broad Scope, But Not "Break New Ground"
Generic Biologics & FDA: "No Recourse" But To Develop Guidance, Crawford Says
FDA Pushing Generic Biologics Timetable In Election Year; "Structure" Expected Soon
FDA Pushing Generic Biologics Timetable In Election Year; "Structure" Expected Soon

Topics

Advertisement
UsernamePublicRestriction

Register

PS059131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel